Hafnium oxide clinical trials
Also written NBTXR3 and JNJ-90301900.
How each study uses hafnium oxide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the hafnium oxide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Johnson & Johnson Enterprise Innovation Inc. (3) · PharmaEngine (2) · Nanobiotix (1) · M.D. Anderson Cancer Center (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test hafnium oxide.
- Apr 2027NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyPhase 1 · Nanobiotix
Studies
Open first, then newest update. How each study uses hafnium oxide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCCRecruitingPhase 3Johnson & Johnson Enterprise Innovation Inc.NCT04892173Written as JNJ-90301900 (NBTXR3)
- A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Johnson & Johnson Enterprise Innovation Inc.NCT06667908Written as JNJ-90301900
- A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingPhase 1Johnson & Johnson Enterprise Innovation Inc.NCT07219212Written as JNJ-90301900
- NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07224152Written as NBTXR3
- NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyActive, not recruitingPhase 1NanobiotixNCT03589339Written as NBTXR3
- A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal CancerTerminatedPhase 1/2PharmaEngineNCT02465593Written as PEP503
- A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck CancerTerminatedPhase 1/2PharmaEngineNCT02901483Written as PEP503
Codes
What other systems call hafnium oxide · ClinicalTrials.gg INT005521
- MeSH (NLM) C545179hafnium oxideOne source NLM
- UNII (FDA) 3C4Z4KG52THAFNIUM OXIDEConfirmed FDA, NLM
- NCI Thesaurus C98280Hafnium Oxide-containing Nanoparticles NBTXR3One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545179 | hafnium oxide | One source NLM |
| UNII (FDA) | 3C4Z4KG52T | HAFNIUM OXIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C98280 | Hafnium Oxide-containing Nanoparticles NBTXR3 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.